Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

JAK Inhibitors Remain the Gold Standard in Myelofibrosis

October 28th 2024

Daniel DeAngelo MD, PhD, discusses the incorporation of JAK inhibitors into the myelofibrosis treatment paradigm.

INCA033989 May Address Need for Disease-Modifying Therapies in Myelofibrosis

October 25th 2024

Daniel J. DeAngelo MD, PhD, discusses the potential role for INCA033989 as a disease-modifying therapy in CALR type 1–mutated myelofibrosis.

Dr Amanam on Currently Available JAK Inhibitors for Myelofibrosis

October 17th 2024

Idoroenyi Amanam, MD, discusses the JAK inhibitors he most commonly reaches for in his clinical practice when treating patients with myelofibrosis.

Dr Klisovic on a Case Discussion of Momelotinib in Myelofibrosis With Anemia

October 16th 2024

Rebecca Klisovic, MD, discusses 3 case studies about patients with myelofibrosis.

Dr Amanam on the Evolution of Myelofibrosis Management

October 11th 2024

Idoroenyi Amanam, MD, discusses potential treatment advancements in myelofibrosis and highlights the use of stem cell transplant in this disease.

Myelofibrosis Treatment Advances Rely on Past Developments to Drive Future Innovation

October 9th 2024

Idoroenyi Amanam, MD, discusses JAK inhibitor–associated AE management and considerations for the future use of stem cell transplant in myelofibrosis.

JAK Inhibitors Diversify the Field of Myelofibrosis Symptom and Spleen Management

October 8th 2024

Idoroenyi Amanam, MD, discusses characteristics that make patients with myelofibrosis most likely to derive benefit from certain JAK inhibitors.

Dr Amanam on Criteria for Selecting a JAK Inhibitor in Myelofibrosis

September 23rd 2024

Idoroenyi Amanam, MD, discusses criteria for selecting patients with myelofibrosis who may benefit from JAK inhibitors.

Tapotoclax Demonstrates Safety, Yields Anti-Leukemic Effects but No Responses in MDS Following HMAs

September 22nd 2024

Tapotoclax showed manageable safety, and it reduced bone marrow blasts and transfusion dependence in MDS after HMAs.

Dr El-Jawahri on the Benefits of Earlier Palliative Care in Hematologic Malignancies

September 20th 2024

Areej El-Jawahri, MD, discusses the potential benefits of earlier palliative care for patients with hematologic malignancies.

Dr Amanam on the Optimal Use of JAK Inhibitors in the Current Myelofibrosis Treatment Paradigm

September 19th 2024

Idoroenyi Amanam, MD, discusses the myelofibrosis treatment paradigm, highlighting patients who may derive the most benefit for JAK inhibitor treatment.

Dr Garcia-Manero on the Association Between Hemoglobin Levels and QOL in Lower-Risk MDS

September 16th 2024

Guillermo Garcia-Manero, MD, discusses the relationship between hemoglobin levels and QOL in patients with lower-risk myelodysplastic syndromes.

FDA Grants Orphan Drug Designation to Tebapivat for MDS

September 12th 2024

The FDA has granted orphan drug designation to tebapivat for the treatment of myelodysplastic syndromes.

Real-World Data for Pacritinib Show Improvement in Thrombocytopenia, Anemia in Myelofibrosis

September 10th 2024

Pacritinib led to improved hematologic outcomes and overall survival in real-world patients with myelofibrosis.

Talazoparib Plus Pacritinib Aims to Improve the Limitations of Second-Line Therapy in MPNs

September 5th 2024

Peter Abdelmessieh, DO, MSC, discusses the phase 1 trial testing the combination of talazoparib and pacritinib in myeloproliferative neoplasms.

Imetelstat Delivers Sustained RBC-TI With No OS Detriment in Lower-Risk MDS

September 5th 2024

Imetelstat sustained red blood cell (RBC) transfusion independence in patients with RBC transfusion–dependent lower-risk myelodysplastic syndrome.

Dr Giralt on Determining Transplant Eligibility in MDS

September 4th 2024

Sergio A. Giralt, MD, discusses how to determine transplant eligibility and the evolving role of transplant for patients with myelodysplastic syndromes.

Dr Grunwald on the Patient Population and Limitations of the REVEAL Study in PV

September 4th 2024

Michael R. Grunwald, MD, FACP, discusses the characteristics of patients with polycythemia vera enrolled in the REVEAL study and limitations of the study.

Revisit Every OncLive On Air Episode From August 2024

August 30th 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2024.

Dr Amanam on the Management of AEs Associated With JAK Inhibitors in Myelofibrosis

August 20th 2024

Idoroenyi Amanam, MD, discusses adverse effects associated with JAK inhibitors in myelofibrosis.